INTRODUCTION
Following the discovery of hepatitis C virus (HCV) in 1989, virus discovery groups searched for novel aetiological agents responsible for non-A, non-B and non-C hepatitis. In the process, human and primate viruses related to HCV were identified. Abbott Laboratories identified two viruses in tamarins which they named GB virus A (GBV-A) and GB virus B (GBV-B) (Schaluder et al., 1995) . The tamarins in which these viruses were identified had been inoculated with the 12th passage of tamarin plasma. The initial tamarin had been inoculated with serum from a surgeon with non-A, non-B hepatitis whose initials were G. B. (Schaluder et al., 1995) . GBV-A and GBV-B were not identified in any human sera (Schaluder et al., 1995) ; however, using degenerate oligonucleotides to amplify related viral sequences, these investigators discovered a human virus which they named GB virus C (GBV-C) . Concurrently, Genelabs Inc. discovered a virus in a patient with HCV infection that they called hepatitis G virus (HGV) (Linnen et al., 1996) . Sequence comparisons revealed that HGV and GBV-C were different isolates of the same species (Linnen et al., 1996) . Based on phylogenetic relationships, the GB viruses and HCV are classified as members of the family Flaviviridae. GBV-A is closely related to GBV-C, and neither virus is associated with hepatitis or any other disease. GBV-B is more closely related to HCV and causes hepatitis in tamarins and owl monkeys (Schaluder et al., 1995) .
GBV-C is a lymphotropic virus associated with improved survival in HIV-infected individuals (Stapleton et al., 2004; Zhang et al., 2006) . The prevalence of GBV-C viraemia ranges from 1 to 5 % in healthy human blood donors and is significantly higher (up to 42 %) in individuals with other blood-borne or sexually transmitted infections (Barnes et al., 2007; Mohr & Stapleton, 2009; Rey et al., 2000; Stapleton, 2003; Thomas et al., 1998; Williams et al., 2004) . GBV-C may cause persistent infection, and approximately 80 % of HIV-infected individuals maintain GBV-C viraemia for at least 5 years . However, the majority of immune-competent individuals appear to clear GBV-C viraemia within 2 years (Hitzler & Runkel, 2004; Theodore & Lemon, 1997; Thomas et al., 1998) . Unlike HCV, antibodies to GBV-C are not readily detected during viraemia (Heuft et al., 1998) ; however, antibodies to the GBV-C envelope glycoprotein E2 are detected in individuals following clearance of viraemia. Concurrent detection of GBV-C E2 antibodies and viraemia is uncommon, with fewer than 7 % of individuals having concurrent anti-E2 antibody and GBV-C viraemia (Lefrère et al., 1997; Sauleda et al., 1999) . Anti-E2 antibodies appear to partially protect against reinfection (Hassoba et al., 1998; Thomas et al., 1998; Tillmann et al., 1998) . Based on the prevalence of E2 antibody to GBV-C RNA in healthy blood donors, it appears that approximately 75-80 % of GBV infections are cleared (Heuft et al., 1998) .
Abbott Laboratories identified a variant of GBV-C (GBV-C trog ) in an HCV-infected chimpanzee with resolving hepatitis (Birkenmeyer et al., 1998) , and reported a nearcomplete genome sequence (GenBank accession no. AF070476) (Birkenmeyer et al., 1998) . Adams et al. (1998) also identified GBV-C RNA in three of 39 noncaptive chimpanzees (subspecies troglodytes and verus) that they called GBV-C cpz . For the remainder of the paper, the chimpanzee variant of GBV-C will be noted with the designation GBV-C cpz rather than GBV-C trog . GBV-C cpz infection was not found in human or macaque monkey blood samples (Birkenmeyer et al., 1998) . The GBV-C cpz polyprotein shares 83.6 % aa identity with GBV-C, while human GBV-C isolates are .95 % identical (Mohr & Stapleton, 2009; Muerhoff et al., 2005; Pavesi, 2001) . Based on limited phylogenetic analysis of sequences from the 59 NTR region, helicase and RNA-dependent RNA polymerase (RdRp), all of the GBV-C cpz sequences are monophyletic within a group of GBV-C viruses from humans and chimpanzees (Adams et al., 1998) . Thus, GBV-C cpz is considered a chimpanzee variant of GBV-C rather than a separate genotype. Sequence analyses of all available chimpanzee GBV-C sequences from Abbott Laboratories (named GBV-C trog ) and Adams et al. (named GBV-C cpz ) demonstrated that these viruses were different isolates of the GBV-C cpz variant (Adams et al., 1998; Birkenmeyer et al., 1998) .
Although Adams et al. detected GBV-C cpz viraemia in three of 39 non-captive chimpanzees and generated partial sequences for one chimpanzee with samples 24 months apart, the prevalence and natural history of GBV-C cpz has not been otherwise examined (Adams et al., 1998) . At the time GBV-C cpz was identified, serological reagents to detect GBV-C E2 antibodies were not available, so there are no data published on the presence of E2 antibodies in chimpanzees. In this study, we examine the prevalence and natural history of GBV-C cpz in a large cohort of captive chimpanzees.
RESULTS

GBV-C cpz prevalence and natural history in captive chimpanzees
Serum samples from 235 captive chimpanzees were tested by nested RT-PCR using primers designed from a human GBV-C 59 NTR sequence (GenBank accession no. AF121950) or by real-time RT-PCR using primers and probe designed to amplify GBV-C cpz . Seven of the 235 (3.0 %) samples contained GBV-C RNA. One of these samples came from the South west Foundation for Biomedical Research (SFBR) and the remaining six samples came from the University of Texas MD Anderson Cancer Center. Sequence analysis was successful for five of the samples (Candie, 1855, P187, 3915 and 3912) and alignments of four of the sequences demonstrated that the sequences aligned more closely with GBV-C cpz than with human GBV-C and one sequence aligned most closely with human GBV-C (Fig. 1a) . Sequence analysis was not successful for two of the seven animals, although GBV-C cpz viraemia is presumed because the amplification was successful only when GBV-C cpz -specific primers were utilized. Two of the GBV-C cpz -positive samples tested positive for all available samples, demonstrating persistent infection of at least 4 or 19 years, respectively (chimpanzees Candie and 1855) (Fig. 1a) . The remaining four animals had transient viraemia with only one sample containing GBV-C cpz RNA (Fig. 1a) .
E2 antibody was detected in 26 of the 235 chimpanzee serum samples (11.1 %). The two persistently infected chimpanzees did not have E2 antibody detected in any of their samples, and one chimpanzee with transient viraemia did not develop E2 antibodies (Fig. 1a) . In contrast, E2 antibodies were detected in the other three GBV-C cpz transiently infected chimpanzees. One of these animals had detectable E2 antibody levels after GBV-C cpz viraemia, consistent with seroconversion, while the other two transiently viraemic animals had E2 antibody detected before and after GBV-C cpz viraemia. The chimpanzee with transient human GBV-C viraemia was also positive for E2 antibody on multiple sample dates surrounding the period of viraemia. None of the chimpanzees received human blood products (Table 1) .
Among the chimpanzees with persistent viraemia (Candie and 1855), the serum viral load remained constant with a mean of 5.3610 8 genome equivalents (GE) ml 21 for chimpanzee Candie and 7.3610 8 GE ml 21 for chimpanzee 1855 over 4 and 19 years, respectively (Fig. 1b) .
Sequences from the 59 NTR and non-structural protein (NS)5A/B coding region were determined at early and late infection time points in the animals with persistent infection, chimpanzees 1855 and Candie (Fig. 2) . No nucleotide changes were observed in a 329 nt sequence from the 59 NTR of chimpanzees 1855 and Candie (data not shown; GenBank accession nos HM626487, HM626488, HM626489 and HM626490). The rate of substitution in a 394 nt segment in the NS5A/B coding region was similarly low, with Candie showing only 1 nt substitution over a 4-year period and 1855 showing 6 nt substitutions over a 16-year period (Fig. 2) . The amino acid sequences of this NS5A/B region from these longitudinal samples were identical in both animals.
Sequence diversity among GBV-C cpz isolates
To study GBV-C cpz NS5A/B sequence heterogeneity, six clones each from chimpanzees Candie and 1855 were compared with the consensus sequence (the sequence which occurs with the highest frequency for each nucleotide position; Ruiz et al., 2010) . Chimpanzee Candie had only one of six clones identical to the consensus sequence after 4 years of infection, resulting in a heterogeneity index of 0.83 (the proportion of GBV-C cpz clones not bearing the predominant sequence) (Fig. 3a) . Chimpanzee Candie demonstrated a mean of 2.8 substitutions per clone in the 394 nt sequence examined, with transitions (A«G or C«T) accounting for 64.7 % of the total number of substitutions. At 16 years post-infection (p.i.), chimpanzee 1855 did not have a predominant nucleotide sequence (Fig. 3b) , which accounted for a heterogeneity index of 1.0, consistent with the prediction of an error-prone RdRp and the generation of quasispecies in serum. Chimpanzee 1855 demonstrated a mean of 4.2 substitutions per clone, and transitions accounted for 84 % of these substitutions (Fig. 3b) . Comparison of nonsynonymous to synonymous substitutions (d N /d S ratio) in the six RdRp sequences demonstrated a ratio of ,0.25 for chimpanzees Candie and 1855, indicating that there was not positive selection. Sequence diversity was not detected in another chimpanzee (3915) with transient GBV-C cpz infection, with all five clones having an identical sequence (heterogeneity index of 0; data not shown; GenBank accession no. HM626492). 
Phylogenetic relationships of GBV-C cpz isolates
Human GBV-C isolates can be grouped into five, or possibly six, genotypes (Muerhoff et al., 2006) . GBV-C, HCV, GBV-A and GBV-B 59 NTR sequences were compared with the published GBV-C cpz 59 NTR sequence (GenBank accession no. AF070476), and the GBV-C cpz and human GBV-C 59 NTR sequences identified in this captive chimpanzee population. As predicted, the newly generated GBV-C cpz sequences and AF070476 form a monophyletic group separate from the human GBV-C sequences (Fig. 4a) .
A GBV-C isolate with a 59 NTR sequence that aligned more closely with human GBV-C sequences from genotype 1 was identified in one chimpanzee (number 3912) (Fig. 4) . This GBV-C isolate was genotype 1, which correlates with African human isolates (Muerhoff et al., 2006) . This animal did not receive human blood products, and the mode of transmission is not known. Since chimpanzees can support experimental human GBV-C infection (Bukh et al., 1998) , and other animals in the colony received human blood products including blood from humans with HIV and HCV infection, it is possible that the animal acquired human GBV-C via intra-colony transmission. Adams et al. (1998) published partial 59 NTR sequences from three non-captive chimpanzees (subspecies troglodytes and verus), including one animal with two samples obtained 24 months apart. The 59 NTR sequences of these isolates share less sequence identity with the published GBV-C cpz sequence (AF070476) and the GBV-C cpz sequences that we characterized (Fig. 4b) , suggesting that GBV-C cpz sequences from non-captive chimpanzees differ from captive chimpanzees. 59 NTR sequences obtained from the chimpanzee of the subspecies verus (chimpanzee 30), are more similar to the GBV-C cpz sequence AF070476 obtained from the subspecies troglodytes than are the sequences from the remaining non-captive chimpanzees (23 and 33), which were also obtained from troglodytes subspecies hosts. Thus, GBV-C cpz infects both subspecies of chimpanzee, troglodytes and verus, and does not strictly cospeciate with either animal host. However, because the newly studied chimpanzees are captive animals, it is possible that the virus was transmitted in captivity, and our results may not accurately reflect the species diversity of GBV-C cpz infection found in the wild.
Phylogenetic relationships are best determined by comparing highly conserved functional domains including regions of the RdRp. The deduced amino acid sequences of GBV-C cpz isolates were determined and compared to the published GBV-C cpz sequence (AF070476), human GBV-C, HCV, GBV-A and GBV-B sequences. The GBV-C cpz NS5B sequences we characterized shared considerable sequence identity with AF070476 and, like the 59 NTR sequences, formed a monophyletic group separate from the human GBV-C genotypes (Fig. 5a ). NS5B sequences generated from non-captive chimpanzees by Adams et al. (1998) diverged from the GBV-C cpz sequences obtained from captive chimpanzees (Fig. 5b) .
The chimpanzee GBV-C cpz RdRp functional motifs, as defined by Koonin (1991) , were highly conserved with human GBV-C sequences. The NS5B sequences from chimpanzees 1855, 3915, Candie and the published GBV-C cpz sequence (AF070476) were identical within the eight RdRp conserved motifs (data not shown). The partial GBV-C cpz NS5B sequences from non-captive chimpanzees only contain sequence for RdRp motifs III and IV and differed from the GBV-C cpz AF070476, chimpanzee 1855, ). Consensus sequences of six quasispecies (as described in Fig. 3 ) from the late infection time points were compared. Arrowhead denotes the putative start side of NS5B and dots represent identical bases. Koonin, 1991) . The four non-captive chimpanzee sequences were identical to the AF070476 sequence in RdRp motif III, and two of the four non-captive chimpanzee sequences (23 and 33) had 1 aa substitution in the RdRp motif IV compared to AF070476 (asparagine to threonine; Fig. 5c ). The substitutions were identical to the human GBV-C RdRp motif IV amino acid sequences instead of the GBV-C cpz AF070476 sequence. In contrast, human GBV-C sequences differ from the AF070476 sequence by up to 3 aa substitutions in RdRp motif III and 2 aa substitutions in RdRp motif IV. The observation that two of the chimpanzees have 1 aa substitution in the RdRp motif IV when compared with the other chimpanzee GBV-C cpz sequences suggests that there is sequence diversity among GBV-C cpz sequences. More GBV-C cpz sequences from captive and noncaptive chimpanzees are necessary to determine whether there are multiple genotypes as with human GBV-C.
DISCUSSION
Human GBV-C infection may persist in human hosts for decades, although the majority of humans studied cleared infection within 2 years following infection (Alter, 1997; Hitzler & Runkel, 2004; Theodore & Lemon, 1997) . Although most GBV-C cpz infections were transient in captive chimpanzees, persistent infection was documented for up to 19 years in one animal. Serum GBV-C cpz viral loads were high and constant in persistently infected animals (~1610 8 GE ml
21
). Thus, GBV-C cpz viral loads are similar to that observed for human GBV-C (Sauleda et al., 1999; Tillmann et al., 2001) . The fact that the animals did not have a documented exposure to human blood products or tissues, and that their viral genome sequences align most closely with chimpanzee GBV-C sequences, suggests that chimpanzee infection was acquired via intracolony transmission (Brook, 1998) .
As with human GBV-C infection, seroconversion may occur with GBV-C cpz clearance, although E2 antibody may be intermittent and was detected before and after GBV-C cpz viraemia. The detection of E2 antibodies prior to the detection of GBV-C cpz viraemia may reflect a GBV-C cpz viral load below the limit of detection of the assay. Of the four chimpanzees that had both viraemia and E2 antibodies detected, three animals had concurrent detection of GBV-C E2 antibodies and viraemia. This prevalence is higher than the prevalence of concurrent viraemia and E2 antibody in humans (7 %) (Lefrère et al., 1997; Sauleda et al., 1999) . E2 antibodies have not been examined in chimpanzee serum prior to this study, and more information is needed to provide a clear understanding of the relationships between E2 antibody and GBV-C cpz viraemia. Nevertheless, the increased frequency of coexisting E2 antibody and viraemia may reflect the limited sample size or suggest that the immune mechanism for clearing human and chimpanzee GBV-C infections differs.
Like human GBV-C, GBV-C cpz quasispecies are detected in serum (Sauleda et al., 1999; Thomas et al., 1998; Tillmann et al., 1998) . GBV-C cpz NS5A/B sequence diversity was detected in chimpanzees with persistent infection and not in a chimpanzee with transient GBV-C cpz infection, suggesting that the generation of sequence diversity may require persistent infection. Human GBV-C quasispecies have nucleotide substitution rates of up to 8.7 % in the 59 NTR region, 2.0 % in the E2 region and 3.3 % in the NS3 region (Ruiz et al., 2010; Zampino et al., 1999) . We found lower rates of GBV-C cpz NS5A/B nucleotide substitution in chimpanzees, with rates of 0.7 % (Candie) and 1.0 % (1855) in the NS5A/B region. None of the substitutions in NS5A/B quasispecies correlated with the mutations observed by Bukh et al. (1998) during the experimental human GBV-C infection of chimpanzees, and most GBV-C cpz nucleotide substitutions in the NS5A/B region were silent mutations. Positive selection was not detected (d N /d S ratio ,1) in the two chimpanzees with persistent infection, suggesting a lack of immunological selective pressure. Even though sequence diversity was detected, a minority of sequences predominated in human GBV-C and GBV-C cpz during persistent infection (Radkowski et al., 1999; Ruiz et al., 2010) . The mutation rate observed between early and late samples during persistent infection was only 0.2-1.5 %, and none of the mutations resulted in a change in the amino acid sequence. RNA secondary structure constraints in the NS5A and NS5B regions of the GBV-C genome may contribute to the low mutation rate over time (Davis et al., 2008; Thurner et al., 2004) .
Given the worldwide distribution and presence of quasispecies of human GBV-C, there is a surprising lack of genetic diversity among human GBV-C isolates. Although few GBV-C cpz sequences are available, the extent of sequence diversity observed between GBV-C cpz isolates may be similar to that of human GBV-C genotypes. More GBV-C cpz sequences need examining to determine if the GBV-C cpz sequence diversity is significant enough to form separate genotypes as with human GBV-C. Adams et al. (1998) found that GBV-C cpz isolates from non-captive chimpanzees of the Pan troglodytes subspecies verus aligned as a separate group from those found in P. troglodytes subspecies troglodytes. The P. troglodytes verus chimpanzees originated from West Africa and P. troglodytes troglodytes animals originated from Cameroon and Nigeria (Adams et al., 1998) . Alignment of the previously published GBV-C cpz sequences and the sequences we characterized does not confirm that GBV-C cpz segregates into separate verus and troglodytes subspecies groups. The GBV-C cpz sequences we studied aligned more closely with GBV-C cpz sequences from non-captive chimpanzees of the subspecies verus, and to a lesser extent with non-captive chimpanzees of the subspecies troglodytes, raising the possibility of interspecies transmission. Chimpanzee inter-subspecies transmission of GBV-C cpz is feasible because human GBV-C can infect both chimpanzees (Bukh et al., 1998) and humans. Our data suggest that it may be more appropriate to call the chimpanzee variant GBV-C cpz to signify that this virus infects both verus and troglodytes subspecies as suggested by Adams et al. (1998) .
Another GB virus, GBV-A, has a species-specific pattern of sequence divergence, and the levels of sequence variation between GBV-A found in different species are similar to the relative sequence distance between human GBV-C and GBV-C cpz . This is consistent with the hypothesis that GBV-C may have evolved with a common ancestor of humans and chimpanzees into the distinct GBV-C and GBV-C cpz variants (Adams et al., 1998) . The similarities of human GBV-C and GBV-C cpz (serum viral load, seroconversion and persistence) and the length of time that each virus has existed in its host since humans and primates evolved separately suggests that chimpanzee GBV-C cpz infection could serve as an animal model of GBV-C-HIV-1 interaction in vivo. Chimpanzees also support experimental infection with human GBV-C with viral loads of 10 6 -10 7 GE ml 21 (Bukh et al., 1998) . Thus, HIV-1 co-infection with either GBV-C or GBV-C cpz could be used to examine HIV-GBV-C interactions in vivo. Finally, it is unclear why human GBV-C or GBV-C cpz viraemia persists in some hosts but not others. The chimpanzee may provide a model to study host factors related to clearance and persistence of infection.
METHODS
Sample identification. Chimpanzee (P. troglodytes troglodytes) serum samples (frozen serum samples) were obtained from repositories located at the SFBR [National Heart, Lung and Blood Institute (NHLBI) colony and South-west National Primate Research Center colony (n581)] San Antonio, TX and from the University of Texas MD Anderson Cancer Center (n5154) Bastrop, TX. A single serum sample was tested for GBV-C RNA, and longitudinal samples were studied in animals that tested positive when available. Samples were also tested for the presence of anti-GBV-C E2 antibodies. Demographic information, infection history and blood product history for GBV-C RNA+ animals are shown in Table 1 .
GBV-C cpz RNA detection. RNA was extracted from chimpanzee serum samples using the QIAamp Viral RNA Mini kit (Qiagen). RNA was stored at 280 uC until use. Reverse transcription was performed using a Moloney murine leukaemia virus reverse transcriptase mutant with reduced RNase H activity (SuperScript II; Invitrogen), and PCR was performed using high-fidelity Taq polymerase (Platinum Taq DNA Polymerase High Fidelity; Invitrogen). Oligonucleotide primers employed are shown in Table 2. PCR products were purified using the QIAquick PCR purification kit (Qiagen), ligated with pCR2.1 (TA Cloning kit, Invitrogen), and INVFa or DH5a competent cells (Invitrogen) were transformed. Six colonies were randomly selected to study sequence diversity. Plasmid DNA was purified (WizardPlus SV Miniprep DNA Purification System; Promega) and sequenced (ABI sequencer; University of Iowa DNA Facility). Nucleotide sequences were entered into GenBank with accession numbers HM626487-HM626506, HM638234-HM638236 and HM769722.
Sequence analysis was performed using DNAman (Linnen, Biosoft) , and phylogenetic and molecular evolutionary analyses were conducted using MEGA version 4 (Tamura et al., 2007) . Sequences were aligned Table 2 . Oligonucleotide primer sequences utilized to detect GBV-C RNA NS5A, Non-structural protein 5A; NS5B, non-structural protein 5B; +, sense primer; 2, antisense primer; Pr, probe sequence.
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with the CLUSTAL W method, evolutionary histories were inferred using the unweighted pair-group method with arithmetic mean (UPGMA) method (Sneath & Sokal, 1973) and bootstrap consensus trees were inferred from 2000 replicates (Felsenstein, 1985) . The evolutionary distances were computed using the Maximum Composite Likelihood method (Tamura et al., 2004) or the Poisson correction method (Zuckerkandl & Pauling, 1965) . d N and d S values were estimated using the Nei-Gojobori method in MEGA4 (Nei & Gojobori, 1986; Tamura et al., 2007) . GBV-C isolates representing the different genotypes were: AB003291, genotype 1; AF121950, genotype 2; U94695, genotype 3; AB003292, genotype 4; and AY949771, genotype 5. Representative isolates of three HCV genotypes were: AF0011753, genotype 1a; AF333324, genotype 1b; D14853, genotype 1c; D00944, genotype 2a; D10988, genotype 2b; and AF046866, genotype 3a. GBV-A (U94421) and GBV-B (AJ277947) sequences were also analysed.
For real-time PCR, RNA was amplified using 59-NTR primers and a 6-carboxyfluorescein/6-carboxytetramethylrhodamine-labelled probe as described previously (Souza et al., 2006) (Table 2 ) using the SuperScript II Platinum One-step Quantitative RT-PCR (Invitrogen) as recommended by the manufacturer. A standard curve was generated using an 842 nt GBV-C 59 NTR (GenBank accession no. AF121950) synthetic RNA and was confirmed for GBV-C amplification by terminal dilution. This standard curve was also used for GBV-C cpz . Results were analysed with 7500 System SDS Software.
E2 antibody detection. Serum samples were tested for E2 antibodies with either the mPlate anti-HGenv test (kindly provided by Dr Georg Hess, Roche Diagnostics, Mannheim, Germany), or by using an inhouse assay when the commercial assay was no longer available. The sensitivity and specificity of the mPlate anti-HGenv test and in-house assay correlated (overall regression50.76). For the in-house assay, Nunc Immobilizer plates were coated with recombinant GBV-C E2 expressed in CHO cells as described previously (McLinden et al., 2006) , blocked with PBS containing 0.02 % Triton X, 0.02 % azide, 1 % BSA and 2.5 % FCS. Serum diluted 1 : 50 was added to the wells for 1 h at 37 uC. Wells were washed and bound antibody was detected using alkaline-phosphatase-labelled anti-human Fc antibodies (Sigma) followed by incubation with p-nitrophenylphosphate (Sigma) diluted in diethanolamine buffer for 1 h at 37 uC. The absorbance was measured at 405 nm after 30 min.
